US Stocks

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals is a pharmaceutical company that creates and sells small molecule protease inhibitors to treat diseases with unmet needs. Their portfolio includes small molecule plasma kallikrein inhibitors that address hereditary angioedema (HAE) and diabetic macular edema (DME), as well as oral plasma kallikrein inhibitors. The company completed a Phase II clinical trial for the treatment of DME and is currently in the preclinical stage of creating an oral inhibitor program that targets an enzyme in HAE.